Literature DB >> 28986121

A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses.

Seung-Keun Hong1, Pui-Kei Wu1, Jong-In Park2.   

Abstract

In addition to its conventional role for cell proliferation and survival, the Raf/MEK/Extracellular signal-regulated kinase (ERK) pathway can also induce growth arrest and death responses, if aberrantly activated. Here, we determined a molecular basis of ERK1/2 signaling that underlies these growth inhibitory physiological outputs. We found that overexpression of ERK1 or ERK2 switches ΔRaf-1:ER-induced growth arrest responses to caspase-dependent apoptotic death responses in different cell types. These death responses, however, were reverted to growth arrest responses upon titration of cellular phospho-ERK1/2 levels by the MEK1/2 inhibitor AZD6244. These data suggest that a cellular threshold for active ERK1/2 levels exists and affects the cell fate between death and growth arrest. We also found that death-mediating ability of ERK2 is abolished by the catalytic site-disabling Lys52Arg replacement or significantly attenuated by the F-site recruitment site-disabling Tyr261Asn replacement, although unaffected by the mutations that disable the common docking groove or the dimerization interface. Therefore, ERK1/2 mediates death signaling dependently of kinase activity and specific physical interactions. Intriguingly, Tyr261Asn-replaced ERK2 could still mediate growth arrest signaling, further contrasting the molecular basis of ERK1/2-mediated growth arrest and death signaling. These data reveal a mechanism underlying the role of ERK1/2 as a focal point of Raf/MEK/ERK-mediated growth arrest and death signaling.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell death; ERK1/2; Growth arrest; MEK1/2; Raf

Mesh:

Substances:

Year:  2017        PMID: 28986121      PMCID: PMC5732048          DOI: 10.1016/j.cellsig.2017.10.001

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  59 in total

Review 1.  The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles.

Authors:  Ehud Wainstein; Rony Seger
Journal:  Curr Opin Cell Biol       Date:  2016-01-29       Impact factor: 8.382

2.  Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity.

Authors:  Kimberly A Burkhard; Fengming Chen; Paul Shapiro
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

3.  Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer.

Authors:  M Adachi; M Fukuda; E Nishida
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

4.  Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice.

Authors:  G Pagès; S Guérin; D Grall; F Bonino; A Smith; F Anjuere; P Auberger; J Pouysségur
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

5.  ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.

Authors:  Eva M Goetz; Mahmoud Ghandi; Daniel J Treacy; Nikhil Wagle; Levi A Garraway
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

6.  Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels.

Authors:  Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

7.  The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site.

Authors:  Kari Callaway; Olga Abramczyk; Lance Martin; Kevin N Dalby
Journal:  Biochemistry       Date:  2007-07-21       Impact factor: 3.162

8.  Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin.

Authors:  D F Lazar; R J Wiese; M J Brady; C C Mastick; S B Waters; K Yamauchi; J E Pessin; P Cuatrecasas; A R Saltiel
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

9.  Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein BimEL.

Authors:  Rebecca Ley; Kathryn Hadfield; Elizabeth Howes; Simon J Cook
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more
  10 in total

1.  Protein Kinase-Mediated Decision Between the Life and Death.

Authors:  Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Echinacoside Induces Mitochondria-Mediated Pyroptosis through Raf/MEK/ERK Signaling in Non-Small Cell Lung Cancer Cells.

Authors:  Ye Shi; Hui Cao; Zhengcheng Liu; Lei Xi; Changqing Dong
Journal:  J Immunol Res       Date:  2022-05-06       Impact factor: 4.493

3.  Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability.

Authors:  Pui-Kei Wu; Seung-Keun Hong; Wenjing Chen; Andrew E Becker; Rebekah L Gundry; Chien-Wei Lin; Hao Shao; Jason E Gestwicki; Jong-In Park
Journal:  Sci Signal       Date:  2020-03-10       Impact factor: 8.192

Review 4.  Mitochondrial Fission Protein 1: Emerging Roles in Organellar Form and Function in Health and Disease.

Authors:  Ugochukwu Kelvin Ihenacho; Kelsey A Meacham; Megan Cleland Harwig; Michael E Widlansky; R Blake Hill
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-25       Impact factor: 5.555

Review 5.  ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer.

Authors:  Reiko Sugiura; Ryosuke Satoh; Teruaki Takasaki
Journal:  Cells       Date:  2021-09-22       Impact factor: 6.600

6.  DMA, a Small Molecule, Increases Median Survival and Reduces Radiation-Induced Xerostomia via the Activation of the ERK1/2 Pathway in Oral Squamous Cell Carcinoma.

Authors:  Palak Parashar; Monoj Kumar Das; Pragya Tripathi; Tejinder Kataria; Deepak Gupta; Deepak Sarin; Puja Panwar Hazari; Vibha Tandon
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

Review 7.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

Review 8.  Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway.

Authors:  Pui-Kei Wu; Andrew Becker; Jong-In Park
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

9.  eIF5A-Independent Role of DHPS in p21CIP1 and Cell Fate Regulation.

Authors:  Andrew E Becker; Pui-Kei Wu; Jong-In Park
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

10.  Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability.

Authors:  Pui-Kei Wu; Seung-Keun Hong; Dmytro Starenki; Kiyoko Oshima; Hao Shao; Jason E Gestwicki; Susan Tsai; Jong-In Park
Journal:  Oncogene       Date:  2020-04-14       Impact factor: 8.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.